Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 8/20 | 0.47 |
| ▸ | PTK6 | Q13882 | 8/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662784 | 0.88 | ERBB2 (0.47) | ERBB2PTK6EGFRIGF1RALK | |
| SCHEMBL676448 | 0.85 | ALK (0.42) | ERBB2PTK6EGFRALK | |
| SCHEMBL676185 | 0.78 | ERBB2 (0.38) | ERBB2PTK6EGFRALKPOLB | |
| SCHEMBL676282 | 0.78 | MAPT (0.45) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL675413 | 0.76 | NPC1 (0.39) | EGFRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3666125 | 0.76 | KCNQ3 (0.42) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3669225 | 0.72 | AURKA (0.47) | ERBB2PTK6EGFRIGF1RALK | |
| SCHEMBL676322 | 0.72 | ALK (0.49) | ERBB2PTK6EGFRALKPOLB | |
| SCHEMBL6896118 | 0.71 | CES2 (0.64) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3666055 | 0.70 | HDAC3 (0.40) | POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | ERBB2 156/4885PTK6 2466/4885EGFR 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.